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Abstract 26 
Silver is used in different applications that result in contact with skin and mucosal surfaces (e.g., jewelry, 27 
wound dressings, or eye drops). Intact skin poses an effective barrier against the absorption of silver. 28 
Mucosal surfaces are observed to be less effective barriers and compromised skin is often a poor barrier. 29 
Silver can deposit as particles in the human body causing a blue-gray discoloration known as argyria. Urine 30 
and feces are reported pathways of excretion. Acute human mortality has been observed following an 31 
abortion procedure involving the intrauterine administration of 7 g silver nitrate (64 mg silver/kg body 32 
weight). Localized argyria has been reported with exposure to silver ions, metallic surfaces, and 33 
nanocrystalline silver. Generalized argyria was observed with ionic and nanocrystalline silver in humans at 34 
cumulative doses in the range of 70 to 1500 mg silver/kg body weight. Silver is observed to have a low 35 
potential for skin irritation. Eye irritation and some cases of allergic contact dermatitis have been reported. 36 
Silver may cause genotoxicity, but additional data are required to assess its carcinogenic potential. Other 37 
reported toxicities include hepatic, renal, neurological, and hematological effects.  38 
 39 
 40 
Keywords: Silver, nanoparticle, nanocrystalline, Acticoat, silver sulfadiazine, toxicology, dermal, eye, 41 
metallic, genotoxicity.  42 
 43 
 44 
  45 
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1. Introduction 46 
Humans are exposed to silver from various sources. Silver is an antibacterial agent in the treatment of burn 47 
wounds, scalds, ulcers, and in the prophylaxis of neonatal conjunctivitis (Moore et al., 2015; Polk, 1966). 48 
Medical devices, such as catheters, transdermal drug delivery devices, acupuncture needles, and sutures, also 49 
contain silver (Lansdown, 2006). Other sources of silver exposure include amalgam fillings, self-medication, 50 
jewelry, deodorants, functional textiles, coins, tableware, coatings in refrigerators, and the workplace (Fluhr 51 
et al., 2010; Hipler et al., 2006; Miller et al., 2010; Nakane et al., 2006; Rongioletti et al., 1992; Schröder et 52 
al., 2012; Stefaniak et al., 2014; Tomi et al., 2004; Wollina et al., 2006; Yamamoto et al., 2012). Physical 53 
forms of silver are ions and metal. The metal encompasses nanoparticles and nanocrystalline coatings. The 54 
aim of this paper is to review the toxicity of silver following in vivo dermal and mucosal surface exposure. 55 
The endpoints genotoxicity and carcinogenicity are considered of very high severity. Therefore, genotoxicity 56 
and carcinogenicity data obtained using all in vivo exposure pathways (not only dermal and mucosal 57 
exposure) are considered as are in vitro data.  In order to obtain all relevant journal articles for the current 58 
review, the following procedure was done. First, references were retrieved from the SciFinder (CAS, 2018) 59 
and Pubmed (Pubmed, 2018) databases, using combinations of appropriate search terms: “silver, 60 
nanoparticle, sulfadiazine, dermal, topical, mucosal, toxicity”. A total of 250 references were obtained and 61 
reviewed using this search strategy. Next, lists of references in relevant journal articles were reviewed to 62 
obtain literature that had not been obtained in database searches. An additional 50 journal articles were 63 
obtained this way. A total of 168 references were deemed relevant and included in the current article. 64 
 65 
2. Absorption, distribution, metabolism, and excretion (ADME) 66 
2.1. Absorption and distribution  67 
A normal level of silver in blood was <1 µg/L, measured in 26 individuals who lived in the Melbourne 68 
metropolitan area. In liver, tissue levels were 0.03 and 0.05 µg silver/g in 2 deceased individuals (Wan et al., 69 
1991). Daily dietary silver intake levels have been reported to be: 0.4 µg/day in a population from Italy 70 
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(Clemente et al., 1977), 7 µg/day, in Canadian women (Gibson and Scythes, 1984) and 27 µg/day in a 71 
population from the United Kingdom (Hamilton et al., 1973). WHO has reported that silver is occasionally 72 
found in drinking water at concentrations above 5 µg/L, and that daily intakes of silver are approximately 7 73 
µg/person (WHO, 2008). Data on absorption of silver over intact skin, mucosal surfaces, and compromised 74 
skin are presented in Figure 1 and detailed in the following sections. 75 
 76 
 77 
 78 
Figure 1. Levels of silver in plasma as a function of dose in humans and rats Legends designate: First 79 
author of the used reference, (animal) species, nature of the silver compound, and nature of the body lining 80 
exposed. For Maitre et al. and Chaby et al., blood levels were reported. Cumulative doses were estimated 81 
based on the number of doses, amount of silver in each dose, and body weights of 0.25 and 70 kg for rats and 82 
humans, respectively. The level of detection in Coombs et al. was 0.5 µg silver/L, illustrated by a vertical 83 
line on the graph. Levels of detection were not reported in any of the other references. “Coombs, human 84 
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silver sulfadiazine, intact skin” was reported as “no elevation of silver” and is depicted as being at the level 85 
of detection. 86 
 87 
2.1.1. Absorption of silver over intact skin 88 
Silver was not absorbed into the blood when human intact skin was exposed to 100 g of 1% silver 89 
sulfadiazine1 cream per day for 2 weeks (~14 mg silver/kg bw/day) (Coombs et al., 1992). In guinea pigs, 2 90 
mL of 0.24 M silver nitrate applied to 3.1 cm2 of intact skin (~138 mg silver/kg bw) resulted in an absorption 91 
of silver ions of less than 1% (Wahlberg, 1965). In rats, a 1% silver sulfadiazine was applied to intact skin on 92 
5 consecutive days (~20 mg silver/kg bw/day), yielding a serum level of 1.5 µg silver/L. Controls had a level 93 
of 1.2 µg silver/L. Levels of silver in liver, kidney, spleen, bone, and brain were equal in control and exposed 94 
animals (Sano et al., 1982). Silver from silver nanoparticles in the size range of tens to hundreds of 95 
nanometer in diameter penetrated into the human stratum corneum. Here it formed aggregates in deeper 96 
layers, likely slowing down penetration of silver into viable skin layers (Bianco et al., 2016). 97 
 98 
2.1.2. Absorption of silver over mucosal surfaces 99 
Silver has been described to cross the human eye mucosa following administration of silver nitrate 100 
(Karcioglu and Caldwell, 1985) and silver cyanide (Schlötzer-Schrehardt et al., 2001). For silver cyanide, 101 
this phenomenon has also been observed in rats (Rungby, 1986). Silver nitrate applied by intrauterine 102 
administration was fatal in one human, indicating uptake over the uterine mucosal surface. The dose was 7 g 103 
of silver nitrate (~64 mg silver/kg bw). In the woman this resulted in a blood level of 3480 µg silver/L, a 104 
urine level of 380 µg silver/L and in organ levels of: 8180 µg silver/kg (liver, tissue wet weight), 6100 105 
(kidney), 2000 (heart), 148 (brain), 1400 (muscle), 140 (fat tissue), and 8200 (placenta). In the fetus organ 106 
                                                     
1
 Silver sulfadiazine is a topical antibacterial agent in which the silver and sulfadiazine moieties are 
pharmaceutically active (Fox, 1975). The literature does not often specify if the mass concentration of SSD 
is weight/weight (w/w). However, for several products, the manufacturers’ descriptions have included the 
(w/w) designation, for example, the Flamazine and Silvadene creams (Pfizer, 2016; 
Smith_&_Nephew_Healthcare_Ltd, 2011). In addition, the (w/w) designation is in compliance with FDA 
recommendations for reporting mass concentrations in topical creams (FDA, 2017). 
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levels were 840 µg silver/kg (liver, tissue wet weight), 400 (lung), 150 (muscle) and less than 10 µg/kg in 107 
kidney, heart and brain. The latter findings suggest that silver is able to pass the placenta (Reinhardt et al., 108 
1971). A woman used silver-containing2 nose drops for 10 years had a serum level of 63 µg silver/L, 109 
indicating that silver is absorbed over the nasal mucosa (Van de Voorde et al., 2005). 110 
 111 
2.1.3. Absorption of silver over skin compromised by burn wounds  112 
An 18-year-old man with a burn wound covering 96% of the body surface was treated with silver nitrate, 113 
resulting in blood and skin levels of 120 µg silver/L and 1,250 mg silver/kg, respectively (Bader, 1966). 114 
Silver sulfadiazine application to burn wounds resulted in serum levels of silver in the range of 2 to more 115 
than 200 µg/L and, in a deceased patient, silver was detected in the liver and kidney (Coombs et al., 1992). 116 
Burn patients administered silver sulfadiazine cream had a mean plasma level of 200 µg silver/L, and silver 117 
was detected in the corneal tissue, liver, and kidney at levels of 970, 14, and 0.2 µg silver/g tissue, 118 
respectively (Wan et al., 1991). When silver sulfadiazine cream was applied to rats, the absorption was low 119 
for a) normal skin (1.2 µg silver/L in serum), b) superficial dermal burn wound with blister (3.4 µg/L) and c) 120 
deep dermal wound (1.5 µg/L); notably, if the superficial dermal wound had the blister removed, silver in 121 
serum increased considerably (13 µg/L). A control group with no silver sulfadiazine application had a level 122 
of 1.2 µg silver/L. In all groups, silver was detected in liver, kidney, spleen, bone, and brain (Sano et al., 123 
1982).  124 
        Nanocrystalline silver dressing3 was applied to 6 patients with burns. A maximum serum level of 200 125 
µg silver/L was measured at 9 days of treatment (Moiemen et al., 2011). Thirty burn patients treated with the 126 
dressing for 11 days had a median serum level of silver of 57 µg/L (Vlachou et al., 2007). In another burn 127 
                                                     
2
 Argyrophedrine nose drops are described to contain 10 mg/mL efedrinelevulinate  and 5 mg/mL silver 
vitellinate. 
3
 Acticoat is a high-density polyethylene mesh with a core of rayon and polyester and coated with 
nanocrystalline silver. It is applied as an antibacterial dressing for the management of burns (Dunn and 
Edwards-Jones, 2004).  
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wound case, the application of nanocrystalline silver dressing for 7 days (~35 mg silver/kg bw/day4) resulted 128 
in a plasma level of 107 µg silver/L (Trop et al., 2006). In rats, dressings containing either silver sulfate or 129 
nanocrystalline silver were applied to burn wounds and changed every week. In weeks 3 and 6, the blood 130 
levels of silver were 136 and 33 µg/kg for silver sulfate and 62 and 168 µg/kg for nanocrystalline silver, 131 
respectively. In the spleen, kidney, and liver, the silver level was higher for nanocrystalline silver, compared 132 
with silver sulfate. Silver was also detected in the brain, testis, lung, heart, and muscle (Pfurtscheller et al., 133 
2014).  134 
 135 
2.1.4. Absorption over skin compromised by other wounds and scalding 136 
A 64-year-old woman was treated for leg ulcers with 100 g 1% silver sulfadiazine cream every week. After 137 
treatment for 18 months, the blood level of silver was 38 µg/L (Maitre et al., 2002). A 61 year-old woman 138 
was treated for ulcers with 200 g silver sulfadiazine cream per day (~9 mg silver/kg bw/day). After 3 weeks 139 
of treatment, the level of silver in blood was 194 µg/L (Chaby et al., 2005). In 40 patients with chronic 140 
wounds treated with different silver preparations, serum silver was observed to correlate to wound area 141 
(Brouillard et al., 2018). Pigs with scalds were applied 1 g of 1% silver sulfadiazine cream for 48 h; 142 
Absorption of silver was less than 1%, but silver was detected in the eye, kidney, lung, stomach, adrenal, 143 
aorta, muscle, spleen, intestine, thyroid, and brain (Lazare et al., 1974).  144 
 145 
2.1.5. Summary of the absorption of silver over skin and mucosal surfaces 146 
Intact skin is observed to pose an efficient barrier against silver. Mucosal surfaces, including in the eye, are 147 
observed to pose a less efficient barrier. When skin is compromised by burns, scalds, or wounds, it is 148 
observed to be more penetrable; specifically, one study showed that uptake highly increased if the wound 149 
blister was removed. Following exposure, silver has been detected in all organs investigated. Detection in the 150 
brain indicates that silver crosses the blood–brain barrier. 151 
                                                     
4
 The dose was estimated using a content of silver of 1 mg/cm2, application to 30% of the total body surface 
area (5700 cm2), and three changes of the dressing during the treatment period.  
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 152 
2.2. Deposition of silver as particles in the body (metabolism) 153 
Dermal metabolism of silver has been reported. Nanocrystalline silver and silver nitrate were administered to 154 
the skin of pigs. With the nanocrystalline form, silver at molecular weights corresponding to Ag, AgO, AgCl, 155 
AgNO3, Ag2O, and so-called silver clusters (Ag2-6) were measured in the epidermis. With silver nitrate 156 
dosage, only AgO, AgCl, AgNO3, and Ag2O were observed (Nadworny et al., 2010). A substantial number 157 
of studies have described the deposition of silver as particles in the body (Supplementary material tables S1 158 
and S2). Deposited particles observed in the skin were of brown or brown-black color at the microscopic 159 
level and differed in sizes: in the range of 10 to 1,000 nm (Kakurai et al., 2003; Matsumura et al., 1992; Sato 160 
et al., 1999; Suzuki et al., 1993; Tanita et al., 1985). In the eyes, the sizes of deposited particles ranged from 161 
15 to 35 nm (Karcioglu and Caldwell, 1985; Schlötzer-Schrehardt et al., 2001). The anatomical localization 162 
of deposited silver-containing particles in the skin were especially a) in the surrounding eccrine glands (13 163 
studies, Supplementary material tables S1 and S2), b) associated with elastic fibers (12 studies), c) in 164 
connection with collagen matrix/fibers (10 studies), d) surrounding small blood vessels (9 studies), and e) 165 
intracellular (8 studies). Regarding intracellular localization, this occurred inside fibroblasts (4 studies) and 166 
macrophages (2 studies) (Supplementary material tables S1 and S2). Subcellular localization was described 167 
as inside lysosomes and free in the cytoplasm (Rongioletti et al., 1992). In eyes, deposited particles were 168 
detected in the cornea, conjunctiva (Rungby, 1986), and other anatomical structures (Supplementary material 169 
table S1).   170 
       Deposited particles, in addition to silver, have also been reported to contain other elements. In 171 
generalized and localized argyria, deposited particles have been reported to contain a) silver and sulfur 172 
(Buckley et al., 1965; Schlötzer-Schrehardt et al., 2001); b) silver and selenium (Loeffler and Lee, 1987; Jan 173 
Aaseth et al., 1981); and c) silver, sulfur, and selenium (Bleehen et al., 1981; Karcioglu and Caldwell, 1985; 174 
Matsumura et al., 1992; Suzuki et al., 1993). The presence of sulfur in the deposited particles can be 175 
explained by the strong affinity of silver to sulfur by the Ag-thiolate binding (Massi and Santucci, 1998). The 176 
formed Ag2S is chemically stable and highly insoluble in water (Liu et al., 2010). It has been suggested that 177 
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sulfur in the deposited particles over time is substituted by selenium to form silver selenide (Massi and 178 
Santucci, 1998; Sato et al., 1999). Silver selenide is chemically more stable than silver sulfide and of even 179 
lower solubility. Additionally, the direct binding of silver to selenium in the enzyme glutathione peroxidase 180 
leading to the direct formation of the chemically stable and inert compound silver selenide has been 181 
suggested (Massi and Santucci, 1998). The serum level of selenium in patients with argyria was the most 182 
critical factor for the presence or absence of selenium within the silver-containing deposited particles, 183 
whereas no relation was observed for factors such as age; sex; the amount, duration, and route of silver 184 
introduced; or the different tissues and organs biopsied (Sato et al., 1999). The formation of the insoluble 185 
silver sulfide and silver selenide have been suggested to reduce the toxic effects of silver ions by reducing 186 
their biological availability (Massi and Santucci, 1998; Sato et al., 1999). Notably, a range studies, including 187 
oral exposure studies, case studies with acupuncture needle implantations, and some occupational studies, 188 
have also demonstrated the deposition of silver and selenium with chloride mercury, titanium, iron, nickel, 189 
sulfur, and osmium (Berry et al., 1995; Berry and Galle, 1982; Bleehen et al., 1981; Matsumura et al., 1992; 190 
Sato et al., 1999; Suzuki et al., 1993; Tanita et al., 1985; J Aaseth et al., 1981).   191 
 192 
 193 
 194 
 195 
 196 
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 197 
 198 
Figure 2. Elimination of silver from plasma after discontinuation of dermal or mucosal exposure in 199 
humans and rats Vertical dotted line illustrates the upper boundary of the normal plasma level of silver 200 
based on (Wan et al., 1991). The level of detection in both Coombs et al. and Pfurtscheller et al. was 0.5 µg 201 
silver/L, illustrated by a vertical line in the graph. Levels of detection were not reported in any of the other 202 
references.  203 
 204 
2.3. Excretion  205 
2.3.1. Time frame for the elimination of silver from blood 206 
Figure 2 presents the literature on the elimination of silver from the blood. A 59-year-old man was treated for 207 
ulcers with 50 g of 1% silver sulfadiazine cream every second day for 5 months (~1 mg silver/kg bw/day). A 208 
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plasma concentration of 10 µg silver/L decreased to 5.1 and 1 µg/L, 3 and 12 weeks after discontinuation, 209 
respectively (Payne et al., 1992). A woman used silver-containing nose drops for 10 years and had a plasma 210 
level of 63 µg silver/L that decreased to 20 µg/L 6 months after discontinuation (Van de Voorde et al., 2005). 211 
In burn wound patients treated with nanocrystalline silver dressing, the mean serum level of silver was 79 212 
µg/L decreasing to 9.7 µg/L and 2.0 µg/L, 3 and 6 months after discontinuation, respectively (Vlachou et al., 213 
2007). Patients with burn wounds were treated with silver nanocrystalline dressings for 9 days. This resulted 214 
in a plasma level of 200 µg silver/L that decreased to 8.2 µg/L 154 days after discontinuation (Moiemen et 215 
al., 2011).  216 
        Collectively, these data suggest that the process of silver elimination from the blood is prolonged, 217 
occurring over the duration of 200 days or more. This phenomenon could be explained by slow excretion or 218 
the continuous mobilization of silver from deposits in tissues. 219 
 220 
2.3.2. Urinary and fecal excretion of silver 221 
A normal urinary excretion rate was reported to be 2 µg silver/day (~1 µg/L) (Wan et al., 1991). In a patient 222 
where silver nitrate was applied for a third degree burn wound covering 96% of the body surface, the urine 223 
level of silver was 38 µg/L (Bader, 1966). In burn wound patients treated with silver sulfadiazine for various 224 
time periods, a urinary threshold level was found at a serum silver level of 100 µg/L: below this serum level, 225 
urinary silver was constantly low (<15 µg/L), and above this serum level, urinary silver was constantly high 226 
(>50 µg/L) (Coombs et al., 1992). In burn patients treated with silver sulfadiazine cream for 10 days, the 227 
mean plasma level of silver was 200 µg/L and urinary excretion rate was 100 µg silver/day (~50 µg/L) (Wan 228 
et al., 1991). In a 61-year-old woman, leg wounds were treated for 3 weeks with 200 g silver sulfadiazine 229 
cream per day. The urine level of silver was 148 µg/L (Chaby et al., 2005). In burn patients treated with 1% 230 
silver sulfadiazine cream for up to 70 days, the urinary peak silver excretion was 1,100 µg/day (~550 µg/L) 231 
(Boosalis et al., 1987). Human burns were treated with nanocrystalline silver dressing for 7 days, and a 232 
plasma level of 107 µg/L was accompanied by a urinary level of 28 µg/L (Trop et al., 2006). Pigs with scalds 233 
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were applied a 1% silver sulfadiazine cream and silver was detected in bile (0.01 % of the dose), feces 234 
(0.02%–0.07% of the dose), and urine (0-0.02 % of the dose) (Lazare et al., 1974).  235 
         In summary, urinary excretion has been observed in humans. In addition, studies in animals have 236 
suggested fecal excretion as an accompanying pathway.  237 
 238 
3. General toxicity - mortality and body weight loss  239 
A pregnant woman had as an abortion procedure 7 g of silver nitrate (~64 mg silver/kg bw) applied in a 7% 240 
water solution by intrauterine administration and died 3½ hours later with symptoms of acute circulatory 241 
insufficiency. The postmortem examination showed erosion of labia paudendi, vagina, uterus, placenta and 242 
of the foetus. Histopathological findings were described as: Acute ingestion of the lungs, kidneys and central 243 
nervous system, as well as pulmonary edema and erosion of the uterine mucosa (Reinhardt et al., 1971). 244 
Burn wound patients were treated with 0.5% silver nitrate solution (2 kg/day/patient, ~90 mg silver/kg 245 
bw/day) for an unspecified period of exposure,5 and no toxicity was observed (Bouterie and McLean, 1971). 246 
Guinea pigs were applied 50 mg of silver as a silver nitrate skin depot (~130 mg silver/kg bw); 8 weeks later, 247 
weight loss was observed. In comparison, mercuric chloride and cobalt chloride at the same molar dose 248 
caused death to more than half of the animal sample (Wahlberg, 1965). Guinea pigs were dermally exposed 249 
to a suspension containing 10–20 nm silver nanoparticles for a time period of 24 h. At the investigated doses, 250 
0.04, 0.2, or 400 mg/kg bw, no effects were observed (Maneewattanapinyo et al., 2011). Similarly, no signs 251 
of toxicity were observed in rats following 24 h of dermal exposure to a suspension containing 10 nm silver 252 
nanoparticles at a dose of 2,000 mg silver/kg (likely per kg bw) (J. S. Kim et al., 2013).  253 
 254 
                                                     
5
 For one patient, the period was reported to be 56 days. 
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4. Argyria 255 
Argyria has been described as blue-gray discoloration of the skin due to the deposition of silver. Argyria can 256 
be localized to the points of exposure (localized argyria) or, with higher exposure, be generalized and 257 
involve areas not directly exposed.  258 
 259 
4.1. Localized argyria 260 
A patient troubled by balanitis applied silver sulfadiazine cream intermittently for 15 years, resulting in 261 
localized argyria on the penis (Griffiths et al., 2006). A surgery wound was applied silver sulfadiazine and 262 
localized argyria was observed (Fisher et al., 2003). Ocular instillation of silver nitrate instillation caused 263 
argyria in the eye (Bartley, 1991), and the use of silver-containing eye drops for many years resulted in 264 
argyria of the lacrimal sac (Loeffler and Lee, 1987).  265 
     Regarding metallic silver, one silversmith had argyria in the fingers (Kamiya et al., 2011) and another in 266 
the fingers and arm (García-Martínez et al., 2016). Localized argyria was observed in jewelry manufacturers, 267 
in skin (Robinson-Bostom et al., 2002) and eyes (Tendler et al., 2017) following the occupational handling 268 
of silver (Nagano et al., 2016) and after exposure to mirror fragments (Hristov et al., 2011). A 40-year-old 269 
woman developed argyria following the accidental imbedding of an acupuncture needle 7 years earlier (Park 270 
et al., 2018). A teenage girl had toxic epidermal necrolysis involving almost 100% of the body surface. She 271 
was treated with nanocrystalline silver dressing for an unspecified period, and 4 years later, localized argyria 272 
was observed (Shaub et al., 2014). A 50-year-old silversmith had approximately 70 blue macules scattered 273 
on his face, limbs, and trunk. These contained silver, sulfur, chloride, phosphorous, silicium, aluminum, 274 
calcium, and potassium. The macules corresponded to sites where silver wires would puncture his skin 275 
(Rongioletti et al., 1992). 276 
        A range of cases have reported localized argyria but without testing for the presence of silver in the 277 
tissue, including cases with dermal exposure to metallic silver (Ferrara et al., 2018; Kapur et al., 2001; 278 
Morton et al., 1996; Palamar, 2010; Shall et al., 1990; Sugden et al., 2001; Utikal et al., 2006; van den 279 
Nieuwenhuijsen et al., 1988) and in the eye after exposure to silver nitrate-coated soft lenses (Hau and Tuft, 280 
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2009). In addition, localized argyria was suggested in a burn patient treated for 10 days with nanocrystalline 281 
silver dressing (~2 mg silver/kg bw/day6) (Zweiker et al., 2014). 282 
 283 
4.2. Generalized argyria 284 
4.2.1. Cases in which generalized argyria was concluded based on the detection of silver in the 285 
discolorations  286 
Generalized argyria developed in a patient with oral ulcers who had her tongue painted with 10% silver 287 
nitrate repeatedly for 1 year (~0.2 mg/kg bw/day7) (Lee and Lee, 1994). Another case was in a 58-year-old 288 
woman who, because of nasal obstruction, had been using silver vitellinate-containing nose drops for 10 289 
years: her serum level was 63 µg silver/L (Van de Voorde et al., 2005). Another case with the use of silver-290 
containing nose drops was reported by (Massi and Santucci, 1998). A 58-year-old man with chronic 291 
laryngitis had self-administered silver over 15 years in the form of a spray containing argento-mercapto-3-292 
hydroxy-2-propane-sodium-sulfonate and m-acetyl-amino-p-hydroxy-phenyl-sodium-arsenate. The 293 
combined cumulative intake of the 2 compounds was estimated to be 360 g. A diffuse blue-gray coloration 294 
of the skin was noticed. The patient died of small cell anaplastic lung carcinoma, and at autopsy, a frank dark 295 
coloration of the renal cortex and choroid plexuses was observed. Silver-containing black granules were 296 
detected in all investigated organs except the brain parenchyma (Gherardi et al., 1984). Other cases in which 297 
generalized argyria were confirmed by the detection of silver in biopsies were a case of using a silver foil-298 
coated mouth refresher over a duration of 20 years (Sato et al., 1999), and a case in a plating factory 299 
employee (Matsumura et al., 1992).  300 
 301 
                                                     
6
 The dose was calculated based on an expected release of 1 mg silver/cm2 and a bw of 70 kg. The dressing 
was changed every 3 days.    
7
 The dose was estimated using an assumed volume of 0.5 mL applied twice a week.  
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4.2.2. Cases in which generalized argyria was diagnosed but not proven by tissue detection of 302 
silver  303 
A 46 year-old woman was extremely pigmented after using silver nitrate for bleeding gingiva 3 times per 304 
week for 26 months. In a liver biopsy, silver colored pigment was observed in portal areas and around central 305 
veins. Over the next 2 years, no substantive decrease in skin pigmentation level was observed. At subsequent 306 
abdominal surgery, the pancreas, stomach, hepatic capsule, spleen, intestines, and peritoneum were all 307 
discolored in a manner similar to the skin. The pancreas was, by far, the most pigmented and appeared silver 308 
colored. Gastric biopsy revealed deposition of what was designated as silver granules in the connective tissue 309 
(Marshall and Schneider, 1977). Nose drops containing 20% silver iodide 6 times a day for 9 years caused 310 
generalized argyria in a 69 year-old man (~0.5 mg silver/kg bw/day8)(Rich et al., 1972). Another case of 311 
argyrosis was in a 45-year-old male who had performed intranasal administration of 10% silver nitrate, or so-312 
called Argyrols,9 for 17 years, using a total volume of ~30 mL/week (i.e., combined volume of the 2 313 
preparations) (Kleckner  Jr., 1949). A 25-year-old woman with severe generalized dystrophic epidermolysis 314 
bullosa was, since early childhood, treated with 1% silver sulfadiazine cream and had developed generalized 315 
argyria. The serum level of silver was 283 µg/L (~0.1 mg silver/kg bw/day) (Flohr et al., 2008). A 23-year-316 
old patient with the same condition was treated, since birth, with applications of silver sulfadiazine cream to 317 
denuded areas 2–3 times a day (~0.1 mg/kg bw/day), resulting in argyria with a serum level of 130 µg 318 
silver/L (Browning and Levy, 2008).  319 
      A 58-year-old man had his throat painted with mild silver protein repeatedly from the age of 3 to 12 and 320 
occasionally used silver protein-containing nose drops. Generalized argyria developed in childhood, but as 321 
he grew up, the abnormal color became less apparent (Pariser, 1978). A 81-year-old woman had developed 322 
generalized argyrosis 40 years earlier when treated for sinusitis with Argyrol for 2 years (Rosenblatt and 323 
                                                     
8
 The dose was estimated using an assumed nose drop volume of 0.05 mL applied 6 times per day. 
9
 So-called silver protein in the form of Argyrol, according to Lancaster, was introduced in 1902 and 
produced by extracting gliadin from wheat and treating it under pressure in an autoclave, obtaining a white 
granular precipitate reported to be the nature of a vitellin. When this protein is combined with silver, the 
resulting product is a dark brown powder containing 30% metal. According to other accounts, the so-called 
vitellin is obtained from serum albumen by hydrolysis (Lancaster, 1920), and it has been reported that the 
metal constitutes only 20% of the preparation (Marshall and Neave, 1906). 
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Cymet, 1987). Generalized argyria also occurred in a 42-year-old man who had used 2, 10 mL bottles of 324 
silver-containing nose drops weekly over the past 4 years to ameliorate allergic rhinitis. One drop contained 325 
0.85 mg of silver protein (Tomi et al., 2004).  326 
        Regarding nanosilver, a 17-year-old male with 30% mixed depth burns was treated for 1 week with 327 
nanocrystalline silver dressing (~35 mg silver/kg bw/day). Generalized argyria was suggested based on a 328 
grayish discoloration of the face. The plasma silver was 107 µg/L (Trop et al., 2006). A patient with toxic 329 
epidermal necrolysis covering 70% of the body surface was treated with 8,000 cm2 of a silver sulfate-330 
containing dressing10 for 7 days. Argyria covering a large part of the body surface was reported. A peak 331 
serum level of silver was 249 µg/L. The patient developed multiorgan system dysfunction and eventually 332 
died (McCague and Joe, 2015).   333 
 334 
4.3. Is argyria a transient or permanent condition? 335 
Argyria has been described as a persistent condition. In one case, argyria in connection with the use of silver 336 
sulfadiazine cream did not diminish over 3 years (Fisher et al., 2003). Some cases, however, have observed 337 
argyria to be reversible. Localized argyria disappeared 3 years after the discontinuation of exposure to 338 
nanocrystalline silver (Zweiker et al., 2014), and generalized argyria following one week of nanocrystalline 339 
silver dressing was reversible (Trop et al., 2006). The insolubility of compounds of silver in combination 340 
with other elements, as previously described, might explain the irreversibility of the coloration of the skin in 341 
some patients with argyria (Sato et al., 1999). 342 
  343 
4.4. Summary of argyria data 344 
Localized argyria has been reported with exposure to silver ions, metallic surfaces, and nanocrystalline 345 
silver. Generalized argyria has been observed with ionic and nanocrystalline silver in humans at cumulative 346 
doses in the range of 70 to 1500 mg silver/kg body weight (Browning and Levy, 2008; Flohr et al., 2008; 347 
                                                     
10
 Mepilex Ag Dressing has been reported contain a silver sulfate preparation that releases silver 
nanoparticles into wounds (Gee Kee et al., 2013).  
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Kleckner  Jr., 1949; Lee and Lee, 1994; Rich et al., 1972). Regarding serum silver levels associated with 348 
generalized argyria, these are in the range of 63–283 µg/L (Browning and Levy, 2008; Flohr et al., 2008; 349 
Trop et al., 2006; Van de Voorde et al., 2005). Humans in which no argyria was reported had silver serum 350 
levels in the range of 0–300 µg/L (Moiemen et al., 2011; Vlachou et al., 2007; Wan et al., 1991).  351 
 352 
 353 
5. Contact dermatitis and eye irritation 354 
5.1. Irritant contact dermatitis and eye irritation 355 
In a controlled clinical trial with 24 patients on topical silver sulfadiazine with standard gauze dressings, no 356 
contact dermatitis was recorded (Genuino et al., 2014). No irritation was found in rabbits having 0.5 mL of a 357 
21% 10 nm silver nanoparticle solution applied to 6 cm2 of skin for 4 h (~16 mg silver/cm2) (J. S. Kim et al., 358 
2013). Pigs were applied with 20 and 50 nm silver nanoparticles at doses of 0.34 or 34 µg/mL/day for 14 359 
days (~0.06 and 6 µg silver/cm2). No gross irritation was observed, but microscopic and ultrastructural 360 
observations showed areas of focal inflammation at a high dose and intracellular edema at a low dose 361 
(Samberg et al., 2010). In rabbits, a 100 cm2 dressing of cotton fabric containing a 2% silver nanoparticles 362 
dispersion was dermally applied. The silver preparation was classified as a barely perceptible irritant (Zelga 363 
et al., 2016). In rabbits, different silver salts were applied to the eyes. All investigated salts, namely, silver 364 
nitrate, silver ammonium nitrate, silver ammonium sulfate, and silver ammonium lactate, were found to 365 
irritate eyes (Calvery, 1941). Further, a 100 mg of 10 nm silver nanoparticles in 21% solution was applied to 366 
one eye of rabbits (~5 mg silver/cm2). Following 3 days of observation, no signs of irritation to the cornea, 367 
iris, or conjunctiva were observed (J. S. Kim et al., 2013). 368 
 369 
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5.2. Allergic contact dermatitis substantiated by patch testing and animal data on skin 370 
sensitization 371 
Silver metal disks and a silver nitrate solution were patch tested, each on the skin of 50 humans having hand 372 
dermatitis. Sensitivity was detected in one patient who was exposed to both silver nitrate and silver metal 373 
(Gaul, 1954) Ozkaya reported a case of allergic contact dermatitis from silver nitrate in a patch test marker 374 
(Ozkaya, 2009). A patient suspected of having a sensitivity reaction to silver sulfadiazine was found to be 375 
sensitive to silver nitrate (Fraser-Moodie, 1992). Positive patch tests for silver nitrate were observed in 2 out 376 
of 118 patients with oral lichenoid lesions topographically related to dental fillings (Laine et al., 1997). In 377 
patients with leg ulcers and contact dermatitis, silver nitrate was found to be an allergen in 12% of the cases 378 
(Jankićević et al., 2008). Contact dermatitis was associated with a positive patch test for silver in a 23-year-379 
old man whose work involved weighing silver (Heyl, 1979). A case of persistent periodontitis was cured by 380 
replacement of all silver amalgam restorations. The patient had a history of developing a rash and swelling 381 
whenever she wore jewelry containing silver. A patch test for silver nitrate was strongly positive (Catsakis 382 
and Sulica, 1978).  383 
         Silver nanoparticles were tested in a guinea pig skin sensitization test, and 1 in 20 animals 384 
demonstrated discrete or patchy erythema, suggesting a weak skin sensitizing effect (J. S. Kim et al., 2013). 385 
In the same assay, a dressing of cotton fabric containing a 2% silver nanoparticles dispersion was classified 386 
as a grade II mild sensitizer (Zelga et al., 2016).  387 
 388 
5.3. Cases in which contact dermatitis was reported but not categorized 389 
A 35-year-old man was treated for a burn wound with silver sulfadiazine twice daily and developed 390 
erythema. Notably, he was also treated with silver sulfadiazine 3 years earlier (McKenna et al., 1995). 391 
Dermatitis was reported following exposure to metallic silver strands incorporated in silken and woolen 392 
fabric (Hollander, 1955). Allergic contact dermatitis to silver was reported in a jeweler (Agarwal and 393 
Gawkrodger, 2002).  394 
      395 
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5.4. Conclusion on contact dermatitis and eye irritation 396 
Overall, silver is observed to have a low potential for skin irritation. Eye irritation has been demonstrated, 397 
and some individuals develop allergic contact dermatitis to silver.  398 
 399 
6. Genotoxicity and carcinogenesis 400 
Silver has been reported to bind to purine and pyrimidine bases in DNA (Goff and Powers, 1975; Luk et al., 401 
1975; Sabbioni and Girardi, 1977), increasing the possibility of it interfering with the normal function of the 402 
genes.  403 
 404 
6.1. Genotoxicity studies in vitro 405 
Details of in vitro genotoxicity studies are presented in Supplementary material table S3. Overall, silver ions 406 
do not indicate mutagenic activity in bacterial assays. An exception is silver iodide, exerting a minor effect in 407 
the TA97 Salmonella typhimurium frameshift strain (Eliopoulos and Mourelatos, 1998). Silver nanoparticles 408 
did not indicate any mutagenic activity in Salmonella typhimurium frameshift and base-pair substitution 409 
strains (Cho et al., 2013; Guo et al., 2016; H. R. Kim et al., 2013; Li et al., 2012). However, a negative Ames 410 
test result for a nanoformulated compound must be taken with caution, because particles may not be able to 411 
penetrate the bacterial cell wall (Landsiedel et al., 2009).  412 
       In the comet assay, silver nanoparticles induced DNA strand breaks in different cell lines (AshaRani et 413 
al., 2009; Eom and Choi, 2010; Stephan Hackenberg et al., 2011; J. S. Kim et al., 2013; Souza et al., 2016). 414 
However, no effect was observed in the NT2 human testicular embryonic cell line nor in primary testicular 415 
cells from mice (Asare et al., 2012). Mouse lymphoma cells were incubated with silver nanoparticles and had 416 
increased DNA strand breaks following co-incubation with oxidizing enzymes (Mei et al., 2012). HK-2 417 
immortalized human proximal tubule cells incubated with silver nanoparticles increased DNA strand breaks 418 
(Kermanizadeh et al., 2013). Silver ions were observed to increase the number of micronuclei in 2 cell lines 419 
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(Guo et al., 2016; Li et al., 2012). Several cell lines were incubated with silver nanoparticles and micronuclei 420 
levels increased in all but one (Kruszewski et al., 2013).  421 
       In chromosomal aberration assays, silver nanoparticles have been positive in 1 of 2 studies (Hackenberg 422 
et al., 2011; J. S. Kim et al., 2013). Regarding gene mutations in mammalian cells, silver ions and 423 
nanoparticles have exerted a positive effect in the mouse lymphoma assay (Guo et al., 2016; Mei et al., 424 
2012). By contrast, silver nanoparticles of different sizes had no effect in the MEF-LacZ cell mutant 425 
frequency assay (Park et al., 2011).  426 
      In summary, silver ions and silver nanoparticles do not induce mutations in bacterial assays. By contrast, 427 
several studies have shown that silver nanoparticles cause primary DNA damage in different cell lines in the 428 
form of DNA strand breaks. In addition, oxidative DNA damage was observed when oxidizing enzymes 429 
were applied. Regarding chromosomal damage, there is an indication that both silver ions and silver 430 
nanoparticles have effects. Finally, silver nanoparticles may induce mutations in mammalian cells; however 431 
more studies are required for clarification.   432 
 433 
6.2. Genotoxicity studies In vivo  434 
Details of in vivo genotoxicity studies are presented in Supplementary material table S4. In jewelry workers 435 
exposed to metallic silver, DNA strand breaks increased in mononuclear leukocytes (Aktepe et al., 2015). 436 
Notably, jewelry workers in addition to skin exposure may also be exposed to silver fumes. Regarding 437 
nondermal pathways, rats were intravenously injected with 20 or 200 nm silver particles. Micronuclei levels 438 
were increased in bone marrow cells, whereas DNA strand break levels were not (Dobrzyńska et al., 2014). 439 
In mice, intravenous injection of silver ions or nanoparticles had no effect on emerging sperm cells with 440 
anomalous head morphology or on DNA strand breaks in spleen cells (Ordzhonikidze et al., 2009). In bone 441 
marrow cells from mice intraperitoneally injected with silver nanoparticles, there were increased 442 
chromosomal aberrations but no increase in DNA strand breaks (Ghosh et al., 2012). Mice dosed by the 443 
same route with silver iodide showed no increase in sister chromatic exchanges in P388 lymphocyte 444 
leukemia cells (Eliopoulos and Mourelatos, 1998). In rats, inhalation of silver nanoparticles induced DNA 445 
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strand breaks in lung cells (Cho et al., 2013), and silver nanoparticles had no effect on micronuclei levels in 446 
bone marrow cells after oral dosing (Kim et al., 2008).  447 
       In summary, metallic silver may induce DNA strand breaks in mononuclear leukocytes. Nanoparticles 448 
increased micronuclei, DNA strand breaks, and the number of sperm cells with anomalous head morphology. 449 
However, additional data are required before firm conclusions can be drawn regarding the genotoxic 450 
potential of silver in vivo.  451 
         452 
6.3. Carcinogenesis  453 
Mice received a dermal application of a 10% silver nitrate solution twice a week for 20 weeks. 7,12-454 
Dimethylbenz[a]anthracene (DMBA) was used as a tumorigenic inducer. There was no promotion of 455 
hyperplasia (Frei and Stephens, 1968). In a similar study design, silver nitrate was dosed twice weekly for 44 456 
weeks. Three out of 22 mice bore a total of 8 papillomas; however, when a single application of croton oil 457 
(5%) was interspersed between DMBA and silver nitrate, 6 out of  20 mice developed a total of 14 tumors, 1 458 
of which was a carcinoma (Saffiotti and Shubik, 1963). Rats had 1.5 cm disks of silver or tin foil embedded 459 
in their abdominal wall. Following a latent period of 275–625 days, 14 tumors (32%) were found in the 460 
silver group. No tumors were found in the tin group. The silver disks were intact, whereas the tin had broken 461 
up and crumbled into a fragmentary mass. It was discussed whether the physical nature of the disks caused 462 
the tumors and not the chemical nature of silver (Oppenheimer et al., 1956). Silver, gold, or platinum disks 463 
(1 mm2 in area) were subcutaneously implanted in rats. No sarcomas were observed at 18 months of 464 
exposure (Nothdurft, 1958). Rats were injected with 2.5 mg colloidal silver per week for 7 months (~1.4 465 
mg/kg bw/day). Argyria developed after 6–8 weeks, and at the end of the 7-month period, 6 out of 26 466 
animals had tumors (spindle cell sarcomas) at the injection site (Schmãhl and Steinhoff, 1960). Rats were 467 
intramuscularly injected with so-called 300 mesh fine silver powder (5 injections of 5 mg followed by 5 468 
injections of 10 mg, ~600 mg/kg bw). The rats were observed for 24 months and silver was not carcinogenic. 469 
The positive control, cadmium, was carcinogenic (Furst and Schlauder, 1978). 470 
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       In summary, the findings point in different directions, and additional studies on are required before a 471 
firm conclusion can be drawn regarding whether silver is carcinogenic.  472 
 473 
7. Other toxicological endpoints 474 
7.1. Neurotoxicity  475 
A 59-year-old man was treated for ulcers with silver sulfadiazine at a dose of 1 mg silver/kg bw/day  every 476 
second day for 5 months (cumulative dose: 160 mg silver/kg bw). Sensation loss was noted over the 477 
forearms and legs (Payne et al., 1992). A woman with generalized dystrophic epidermolysis bullosa was 478 
treated with silver sulfate cream over the course of many years (~0.1 mg silver/kg bw/day). She developed a 479 
loss of proprioception, a tingling sensation in her limbs, and impaired coordination  (Flohr et al., 2008).   480 
 481 
7.2. Hepatic toxicity  482 
Burn patients treated with silver sulfadiazine for various time periods had elevated liver enzyme activities 483 
that correlated to serum levels of silver (Coombs et al., 1992). A 17-year-old male burn patient was treated 484 
with nanocrystalline silver dressing for one week with (~35 mg silver/kg bw/day). Liver enzymes were 485 
upregulated during exposure but normalized upon discontinuation of the dressing (Trop et al., 2006).  486 
 487 
7.3. Renal toxicity 488 
Following the treatment of burns with a 0.5% silver nitrate solution, argyria with depletion of body sodium 489 
chloride was observed in 1 out of 15 patients (Moyer et al., 1965). Renal dysfunction developed  in a woman 490 
treated with 100 g of 1% silver sulfadiazine cream per week for 18 months (~0.6 mg/kg bw/day or a 491 
cumulative dose of ~325 mg/kg bw). The level of silver in blood was 38 µg/L. However, a female burn 492 
wound patient treated with silver sulfadiazine and having a silver blood concentration of 440 µg/L had 493 
normal renal function (Maitre et al., 2002). A burn wound developing after the spraying of a ruptured 494 
conduit that contained 60% sulfuric acid and 40% nitric acid at 60°C was treated with silver sulfadiazine for 495 
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60 days, during which nephrotic syndrome developed. Improved renal function and remission of proteinuria 496 
occurred after 5 months of therapy with immunosuppressive agents (Owens et al., 1974). A 61-year-old 497 
woman with ulcers was treated with 200 g of silver sulfadiazine cream daily for 3 weeks and developed renal 498 
failure (~180 mg silver/kg bw). The blood level of silver was 196 µg/L. The signs regressed upon withdrawal 499 
of the cream and after several sessions of hemodialysis (Chaby et al., 2005). A woman with a burn covering 500 
70% of the total body surface area was treated with 8,000 cm2 silver-containing silicone foam dressing for 7 501 
days and developed kidney failure. She subsequently developed multiorgan system dysfunction and 502 
eventually died (McCague and Joe, 2015). 503 
 504 
7.4. Hematological toxicity  505 
There are several reports that indicate leukopenia is associated with the use of silver sulfadiazine in humans 506 
(Caffee and Bingham, 1982; Chaby et al., 2005; Chan et al., 1976; Fraser and Beaulieu, 1979; Gbaanador et 507 
al., 1987; Jarrett et al., 1978; Lockhart et al., 1983; Valente and Axelrod, 1978; Viala et al., 1997; Wilson et 508 
al., 1986). In support of this assertion, silver sulfadiazine was applied to mice with full-thickness skin 509 
excision covering 10% of the body surface, resulting in a reduction in total peripheral blood leukocyte counts 510 
(Gamelli et al., 1993). The findings of 2 controlled human studies have not supported that silver sulfadiazine 511 
induces leukopenia (Kiker et al., 1977; Thomson et al., 1989), and neutropenia sometimes occurs as an 512 
adverse effect of sulfadiazine in the absence of silver (Chen et al., 1991; Finland et al., 1984; Marshall et al., 513 
1950; McMillin, 1951; Trepanier, 2004). However, in absence of sulfadiazine, leukopenia was reported in a 514 
burn patient treated with a silver-containing silicone foam dressing for 7 days (McCague and Joe, 2015). 515 
      Methemoglobinemia secondary to dermal silver nitrate therapy has been reported (Chou et al., 1999; 516 
Cushing and Smith, 1969; Strauch et al., 1969a, 1969b). Methemoglobinemia was also reported following 517 
the exposure to nitrate alone; thus, nitrate and not silver may be responsible for the effect (Inoue et al., 1999).  518 
 519 
8. Comparison of ionic and nanoparticulate silver 520 
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Silver nanoparticles could be expected to act differently than silver ions: 1) they could act as a physical 521 
entity, for example, by breaking a cell wall or obstructing a vessel (only free nanoparticles); 2) they could 522 
provide a surface milieu in which chemical reactions could occur or molecules be absorbed and immobilized; 523 
or 3) they could release ions. The release of silver ions from the surface of metallic silver has been 524 
demonstrated in vivo (Danscher and Locht, 2010). The studies described in the present review that compare 525 
silver ions with nanoparticles and nanocrystalline coatings use animals and indicate a similar effect of silver 526 
ions and nanoformulated silver (Guo et al., 2016; Korani et al., 2013; Li et al., 2016; Nadworny et al., 2010; 527 
Ordzhonikidze et al., 2009; Pfurtscheller et al., 2014); and this is also observed to be the case for oral 528 
exposure to silver (Hadrup et al., 2012; Hadrup and Lam, 2014). One dermal exception is a study in which 529 
skin irritation was observed with silver nanoparticles but not silver nitrate (Koohi, M K; Hejazy, M; Asadi, 530 
F; Asadian, 2011).  531 
 532 
9. Risk characterization 533 
The question is, what are the critical effects of dermal and mucosal silver? The 7 g dosage of intrauterine 534 
silver nitrate  as an abortion procedure caused mortality. This dose corresponds to 64 mg silver/kg bw. In 535 
guinea pigs, 130 mg silver/kg bw given as a skin depot caused weight loss. Regarding generalized argyria, 536 
this has been reported in humans with estimated cumulative doses as low as 70 mg/kg bw (Lee and Lee, 537 
1994). Collectively, these findings suggest that critical effects start to occur at cumulative doses in the range 538 
of 60 to 70 mg silver/kg bw. Regarding the ultimate endpoint of genotoxicity and carcinogenicity, the 539 
evidence is conflicting as to the role of silver; although most have been negative, more studies on the 540 
carcinogenic potential would be relevant. 541 
 542 
10. Summary 543 
By the dermal and mucosal surface exposure route, intact skin is observed to be an effective barrier; 544 
however, silver is taken up through the mucosal surfaces and compromised skin. Deposition occurs in a 545 
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range of organs and involves deposition as particles in the form of silver combined with other elements, 546 
including sulfur and selenium. The deposition of silver as particles causes discoloration known as argyria. 547 
Excretion after exposure by the dermal and mucosal surface routes involves increased levels in urine and 548 
feces. The elimination from plasma is prolonged, lasting several of hundreds of days.  549 
     Regarding toxicity, a case of mortality was observed at intrauterine exposure to ionic silver at 64 mg/kg 550 
bw. Localized argyria has been reported with exposure to silver ions, metallic surfaces, and nanocrystalline 551 
silver. Generalized argyria was observed with ionic and nanocrystalline silver in humans at cumulative doses 552 
in the range of 70 to 1500 mg silver/kg body weight. Silver is observed to have a low potential for skin 553 
irritation. Eye irritation and some cases of allergic contact dermatitis have been reported. Silver may cause 554 
genotoxicity, but additional data are required to assess its carcinogenic potential. Other reported toxicities 555 
include hepatic, renal, neurological, and hematological effects.  556 
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Highlights  
(Toxicity of silver ions, metallic silver, and silver nanoparticle materials after in vivo 
dermal and mucosal surface exposure: a review) 
 
1. Silver is an ingredient in certain dermal and mucosal medical applications  
2. Silver can deposit in the body as particles causing a discoloration called argyria  
3. Silver is observed to have a low potential for skin irritation. Eye irritation and allergic contact dermatitis 
have been reported 
4. Silver may cause genotoxicity, but additional data on its carcinogenic potential are required 
